Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis

BACKGROUND: The aim of the study was to evaluate the cost-effectiveness of nivolumab plus chemotherapy as first-line treatment for patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma from the perspective of Chinese and US society. METHODS: To conduct the ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peng-Fei, Shi, Xuan-Qiong, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500934/
https://www.ncbi.nlm.nih.gov/pubmed/37705023
http://dx.doi.org/10.1186/s12962-023-00476-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500934/
https://www.ncbi.nlm.nih.gov/pubmed/37705023
http://dx.doi.org/10.1186/s12962-023-00476-2

Ejemplares similares